Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-109983
Filing Date
2025-11-13
Accepted
2025-11-13 16:07:38
Documents
60
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0260960-10q_relmada.htm   iXBRL 10-Q 532215
2 CERTIFICATION ea026096001ex31-1_relmada.htm EX-31.1 11311
3 CERTIFICATION ea026096001ex31-2_relmada.htm EX-31.2 11140
4 CERTIFICATION ea026096001ex32-1_relmada.htm EX-32.1 4418
5 CERTIFICATION ea026096001ex32-2_relmada.htm EX-32.2 4454
  Complete submission text file 0001213900-25-109983.txt   4117170

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE rlmd-20250930.xsd EX-101.SCH 39222
7 XBRL CALCULATION FILE rlmd-20250930_cal.xml EX-101.CAL 25826
8 XBRL DEFINITION FILE rlmd-20250930_def.xml EX-101.DEF 215642
9 XBRL LABEL FILE rlmd-20250930_lab.xml EX-101.LAB 385085
10 XBRL PRESENTATION FILE rlmd-20250930_pre.xml EX-101.PRE 229807
63 EXTRACTED XBRL INSTANCE DOCUMENT ea0260960-10q_relmada_htm.xml XML 353324
Mailing Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134
Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39082 | Film No.: 251478444
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)